Tillotts Pharma Ag
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1986-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.tillotts.com
Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 18
- Registration Number
- NCT02911298
- Locations
- 🇨🇭
University Hospital Basel, Phase I Research Unit, Basel, Basel-Stadt, Switzerland
TP0502-B-Pharmaco-Scintigraphic-Study
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 9
- Registration Number
- NCT02306798
TP0501 - Pharmaco-Scintigraphic-Study
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: TP05 Coating ADrug: TP05 Coating B
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 18
- Registration Number
- NCT02306772
TP0502-Pharmaco-Scintigraphic-Study and Amendment
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: TP05 Coating DDrug: TP05 Coating HDrug: TP05 Coating E
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 26
- Registration Number
- NCT02306785
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 817
- Registration Number
- NCT01903252
- Locations
- 🇨🇭
Tillotts Pharma AG, Rheinfelden, Baslerstrasse 15, Switzerland
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 251
- Registration Number
- NCT01257386
- Locations
- 🇨🇳
Shanghai Hospital, Shanghai, China
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 251
- Registration Number
- NCT01257399
- Locations
- 🇨🇳
Shanghai Hospital, Shanghai, China
Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Mesalamin
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 281
- Registration Number
- NCT01059344
- Locations
- 🇧🇾
Gomel Regional Clinical Hospital, 9, Gomel, Belarus
🇧🇾City Clinical Hospital No.1, Minsk, Belarus
🇧🇾Minsk Regional Clinical Hospital, 41, Minsk, Belarus
EPANOVA in Crohn's Disease, Study 1
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 384
- Registration Number
- NCT00613197
- Locations
- 🇧🇪
University of Leuven, Leuven, Belgium
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn's Disease
- First Posted Date
- 2003-12-16
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 364
- Registration Number
- NCT00074542
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States